Incidence of Exacerbations and Hospitalizations Is Reduced and Time to Exacerbations Is Prolonged with Mometasone Furoate Dry Powder Inhaler Versus Beclomethasone Dipropionate Hydrofluoroalkane Aerosol in Patients with Mild Asthma
Health Outcomes Research in Medicine · 2010
DOI: 10.1016/j.ehrm.2010.08.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Outcomes Research in Medicine, 2010. Verfasst von Prakash Navaratnam und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Navaratnam, P., Urdaneta, E., McLaughlin, J., & Friedman, H. S. (2010). Incidence of Exacerbations and Hospitalizations Is Reduced and Time to Exacerbations Is Prolonged with Mometasone Furoate Dry Powder Inhaler Versus Beclomethasone Dipropionate Hydrofluoroalkane Aerosol in Patients with Mild Asthma. Health Outcomes Research in Medicine. https://doi.org/10.1016/j.ehrm.2010.08.001
Vancouver
Navaratnam P, Urdaneta E, McLaughlin J, Friedman HS. Incidence of Exacerbations and Hospitalizations Is Reduced and Time to Exacerbations Is Prolonged with Mometasone Furoate Dry Powder Inhaler Versus Beclomethasone Dipropionate Hydrofluoroalkane Aerosol in Patients with Mild Asthma. Health Outcomes Research in Medicine. 2010. doi:10.1016/j.ehrm.2010.08.001
BibTeX
@article{Navaratnam2010,
author = {Navaratnam, Prakash and Urdaneta, Eduardo and McLaughlin, John and Friedman, Howard S.},
title = {Incidence of Exacerbations and Hospitalizations Is Reduced and Time to Exacerbations Is Prolonged with Mometasone Furoate Dry Powder Inhaler Versus Beclomethasone Dipropionate Hydrofluoroalkane Aerosol in Patients with Mild Asthma},
journal = {Health Outcomes Research in Medicine},
year = {2010},
doi = {10.1016/j.ehrm.2010.08.001}
}
EUVIMED